trending Market Intelligence /marketintelligence/en/news-insights/trending/ABN-p34PUIg8_Ndtf08KJg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biogen Q3 profit climbs 13.1% YOY as Spinraza boosts revenue growth

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Biogen Q3 profit climbs 13.1% YOY as Spinraza boosts revenue growth

Biogen Inc. said its third-quarter non-GAAP net income came to $9.17 per share, compared with the S&P Global Market Intelligence consensus normalized EPS estimate of $8.27.

EPS increased 23.9% year over year from $7.40.

Non-GAAP net income totaled $1.69 billion, an increase of 13.1% from $1.49 billion in the prior-year period.

Total revenues climbed year over year to $3.60 billion from $3.44 billion, and research and development expenses increased 6.4% from the prior-year period to $540.4 million from $507.9 million.

The Cambridge, Mass.-based biotechnology company said revenue growth was partly attributed to neuromuscular drug Spinraza, which raked in $547 million in revenues during the third quarter.

GAAP net income increased 7.1% on an annual basis to $1.55 billion, or $8.39 per share, from $1.44 billion, or $7.15 per share.

Year-to-date through Sept. 30, the company's non-GAAP net income totaled $25.22 per share, a gain from $19.22 per share in the prior-year period.

Non-GAAP net income was $4.81 billion, a gain from $3.98 billion in the prior-year period.

Year-to-date total revenues rose 7.9% from the prior-year period to $10.71 billion from $9.93 billion.